Trials / Completed
CompletedNCT00732368
A Long-term Study of Mometasone Furoate in Patients With Perennial Allergic Rhinitis (Study P04459)
A Long-term Study of Mometasone Furoate in Patients With Perennial Allergic Rhinitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 98 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
This study examined the safety and effectiveness of long-term administration of mometasone nasal spray in patients with perennial allergic rhinitis. Patients received mometasone for 12 weeks plus an additional 12 weeks if patient agreed to continue. Dose of mometasone could be decreased or increased during the study based on patient's response.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mometasone furoate | Two sprays mometasone nasal spray per nostril once daily (200 mcg/day). After 4 weeks, dose can be decreased to one spray per nostril daily or increased to 4 sprays per nostril daily. |
Timeline
- Start date
- 2005-05-01
- Primary completion
- 2006-01-01
- Completion
- 2006-01-01
- First posted
- 2008-08-12
- Last updated
- 2024-08-15
Source: ClinicalTrials.gov record NCT00732368. Inclusion in this directory is not an endorsement.